TRPC6抑制剂BI 764198降低COVID-19相关ARDS风险与严重性的II期随机对照试验
这项多中心双盲II期随机对照试验纳入需非侵入性氧疗的COVID-19住院患者,比较每日口服BI 764198(n=65)与安慰剂(n=64)28天。主要终点第29天存活且无需机械通气比例无差异(83.1% vs 87.5%,风险差-5.39%,95%CI -16.08至5.30,p=0.323)。次要终点显示BI 764198组首次应答时间更长、住院时间延长,且致死事件更多,试验因无效及致死事件不平衡提前终止。
要点
- TRPC6抑制剂BI 764198未降低COVID-19患者ARDS风险或严重性。
- 主要终点第29天存活且无机械通气比例两组无显著差异。
- BI 764198组致死事件更多(7例 vs 2例),试验提前终止。
核心结论
- TRPC6抑制未能降低需非侵入性氧疗的COVID-19患者ARDS风险与严重性。
研究设计与样本
- 多中心、双盲、随机II期试验,比较每日口服BI 764198(n=65)与安慰剂(n=64)28天,随访2个月。
主要发现
- 主要终点第29天存活且无需机械通气比例:BI 764198组83.1% vs 安慰剂组87.5%,风险差-5.39%(95%CI -16.08至5.30,p=0.323)。
- 首次应答时间延长(率比0.67,95%CI 0.46至0.99,p=0.045)。
- 住院时间延长(+3.41天,95%CI 0.49至6.34,p=0.023)。
- 治疗期间不良事件两组相似,致死事件BI 764198组7例 vs 安慰剂组2例。
临床怎么用
- 不推荐对需非侵入性氧疗的COVID-19患者使用TRPC6抑制剂BI 764198以预防ARDS。
局限性
- 试验因无效及致死事件不平衡提前终止,样本量有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Despite the availability of COVID-19 vaccinations, there remains a need to investigate treatments to reduce the risk or severity of potentially fatal complications of COVID-19, such as acute respiratory distress syndrome (ARDS). This study evaluated the efficacy and safety of the transient receptor potential channel C6 (TRPC6) inhibitor, BI 764198, in reducing the risk and/or severity of ARDS in patients hospitalised for COVID-19 and requiring non-invasive, supplemental oxygen support (oxygen by mask or nasal prongs, oxygen by non-invasive ventilation or high-flow nasal oxygen). METHODS: Multicentre, double-blind, randomised phase II trial comparing once-daily oral BI 764198 (n=65) with placebo (n=64) for 28 days (+2-month follow-up). PRIMARY ENDPOINT: proportion of patients alive and free of mechanical ventilation at day 29. Secondary endpoints: proportion of patients alive and discharged without oxygen (day 29); occurrence of either in-hospital mortality, intensive care unit admission or mechanical ventilation (day 29); time to first response (clinical improvement/recovery); ventilator-free days (day 29); and mortality (days 15, 29, 60 and 90). RESULTS: No difference was observed for the primary endpoint: BI 764198 (83.1%) versus placebo (87.5%) (estimated risk difference -5.39%; 95% CI -16.08 to 5.30; p=0.323). For secondary endpoints, a longer time to first response (rate ratio 0.67; 95% CI 0.46 to 0.99; p=0.045) and longer hospitalisation (+3.41 days; 95% CI 0.49 to 6.34; p=0.023) for BI 764198 versus placebo was observed; no other significant differences were observed. On-treatment adverse events were similar between trial arms and more fatal events were reported for BI 764198 (n=7) versus placebo (n=2). Treatment was stopped early based on an interim observation of a lack of efficacy and an imbalance of fatal events (Data Monitoring Committee recommendation). CONCLUSIONS: TRPC6 inhibition was not effective in reducing the risk and/or severity of ARDS in patients with COVID-19 requiring non-invasive, supplemental oxygen support. TRIAL REGISTRATION NUMBER: NCT04604184.
引用
- Ware LB, Soleymanlou N, McAuley DF, et al. TRPC6 inhibitor (BI 764198) to reduce risk and severity of ARDS due to COVID-19: a phase II randomised controlled trial. Thorax. 2023. PMID: 37024277. doi:10.1136/thorax-2022-219668
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。